Cite
HARVARD Citation
Janku, F. et al. (n.d.). Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor. European journal of cancer. pp. S2-S3. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Janku, F. et al. (n.d.). Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor. European journal of cancer. pp. S2-S3. [Online].